Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleuk… Read more
Medicenna Therapeutics Corp (MDNAF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.482x
Based on the latest financial reports, Medicenna Therapeutics Corp (MDNAF) has a cash flow conversion efficiency ratio of -0.482x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.94 Million) by net assets ($10.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medicenna Therapeutics Corp - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Medicenna Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medicenna Therapeutics Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medicenna Therapeutics Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Samick Thk
KO:004380
|
0.064x |
|
DK-Lok Corporation
KQ:105740
|
0.012x |
|
Pruksa Holding Public Company Limited
F:2PR3
|
-0.010x |
|
Farmers and Merchants Bancshares Inc
PINK:FMFG
|
0.034x |
|
JW Shinyak Corporation
KQ:067290
|
0.115x |
|
GENTIAN DIAGNOST. NO -01
F:6FK
|
N/A |
|
APEX International Financial Engineering Res & Tech Co Ltd
TWO:5210
|
0.016x |
|
Bourse Direct SA
PA:BSD
|
0.089x |
Annual Cash Flow Conversion Efficiency for Medicenna Therapeutics Corp (2014–2025)
The table below shows the annual cash flow conversion efficiency of Medicenna Therapeutics Corp from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $19.09 Million | $-16.49 Million | -0.864x | +72.43% |
| 2024-03-31 | $5.19 Million | $-16.26 Million | -3.132x | -629.72% |
| 2023-03-31 | $29.49 Million | $-12.66 Million | -0.429x | +62.08% |
| 2022-03-31 | $20.84 Million | $-23.58 Million | -1.132x | -182.01% |
| 2021-03-31 | $38.15 Million | $-15.31 Million | -0.401x | -62.04% |
| 2020-03-31 | $36.15 Million | $-8.95 Million | -0.248x | +91.94% |
| 2019-03-31 | $2.62 Million | $-8.04 Million | -3.072x | +34.41% |
| 2018-03-31 | $2.16 Million | $-10.12 Million | -4.683x | -326.75% |
| 2017-03-31 | $6.66 Million | $-7.31 Million | -1.097x | +4.17% |
| 2016-03-31 | $2.24 Million | $-2.57 Million | -1.145x | -102.51% |
| 2015-03-31 | $-19.30K | $-880.32K | 45.603x | +1865.98% |
| 2014-03-31 | $-267.05K | $-619.44K | 2.320x | -- |